[MEDP] Medpace Holdings Thesis 2026: Mid-Cap Biotech CRO Cycle Drives Backlog Conversion Recovery
Medpace Holdings Inc. (NASDAQ: MEDP) FY2025 revenue ~$2.3-2.5B (+8-15%) with adj. EPS ~$13.50-15.00 reflecting continued post-2024 ~$3.0-3.3B aggregate backlog (~+5-10% YoY) + selected continued post-2024 selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services under continued President + CEO August Troendle since 1992 (~33-year tenure as Medpace Founder + CEO; selected ~25%+ Troendle family + Founder family aggregate ownership). One of the largest US mid-cap + small-cap biotech-focused Contract Research Organizations (CRO). Founded 1992 as Medpace by August Troendle (~33-year heritage); selected post-2014 ~$915M aggregate Cinven (UK-based private equity) acquisition; selected post-August 2016 NASDAQ listing IPO via secondary offering (~$255M aggregate raised). Headquartered in Cincinnati Ohio; ~6,000+ employees globally with ~$2.3-2.5B revenue. One primary segment: Clinical Trial Services + Selected Various (~100% ~$2.3-2.5B). End market mix: Mid-cap + small-cap biotech ~80%+ + Large-cap pharma ~10% + Government ~5-10%. Therapeutic mix: Oncology ~30%+ + Cardiology + Metabolic ~20% + Neurology + CNS ~15-20% + Antiviral + Infectious Disease ~10% + selected various ~25-30%. Mid-cap biotech CRO cycle: ~$3.0-3.3B aggregate backlog; selected primary mid-cap biotech + small-cap biotech CRO market leadership; biotech funding + clinical trial demand recovery. Therapeutic-focused clinical trial services: oncology + cardiology + neurology + therapeutic-focused capability. President + CEO August Troendle since 1992 (~33-year tenure); CFO Kevin Brady. Capital + cash position: ~$300-450M aggregate cash + investments balance; ~$0M aggregate net debt position; modest opportunistic buybacks; ~$300-500M aggregate FY2024-2025 buyback program (~$150-300M aggregate FY2025); aggregate capital return ~$150-300M; selected ~25%+ Troendle family + Founder family aggregate ownership; investment-grade pathway pre-credit-rating. FY2026 thesis: Mid-cap biotech CRO cycle + Therapeutic-focused clinical trial services + selected continued post-2024 selected various biotech funding + clinical trial demand recovery + ~$300-500M aggregate cash + investments balance + ~$0M aggregate net debt + ~$150-400M aggregate annual buybacks + selected continued ~25%+ Troendle family + Founder family aggregate ownership + selected potential post-2024 dividend initiation. Risks: mid-cap biotech CRO cyclical, IQVIA + ICON + Charles River competition, biotech funding cycle, clinical trial cancellation, ~25%+ Troendle family ownership concentration.
[MEDP] Medpace Holdings Thesis 2026: Mid-Cap Biotech CRO Cycle Drives Backlog Conversion Recovery
Key Takeaways
- Medpace Holdings Inc. (NASDAQ: MEDP) FY2025 revenue ~$2.3-2.5B (+8-15% YoY) with adj. EPS ~$13.50-15.00 reflecting continued post-2024
$3.0-3.3B aggregate backlog (+5-10% YoY) plus selected continued post-2024 selected primary mid-cap biotech + selected various small-cap biotech CRO (Contract Research Organization) market leadership + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services under continued President + CEO August Troendle since 1992 (~33-year tenure as Medpace Founder + CEO; ex-various pharmaceutical industry roles + ~40+-year industry career; selected ~25%+ Troendle family + Founder family aggregate ownership). - Mid-cap biotech CRO cycle:
$2.3-2.5B aggregate revenue FY2025 (+8-15% YoY); selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership; selected continued post-2024$3.0-3.3B aggregate backlog (+5-10% YoY); selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services + selected various biotech funding + selected various clinical trial demand recovery; selected continued post-2024 ~$0.50-0.80 incremental annual EPS contribution. - Therapeutic-focused clinical trial services: selected continued post-2024 selected primary therapeutic-focused (oncology + cardiology + neurology + selected various) clinical trial service capability + selected various US + selected various international clinical trial site network + selected various ~$0.20-0.30 incremental annual EPS contribution from selected various therapeutic mix expansion.
- Capital + cash position: selected post-2024 ~$300-450M aggregate cash + investments balance; selected post-2024 ~$0M aggregate net debt position; selected modest opportunistic buybacks; selected
$300-500M aggregate FY2024-2025 buyback program ($150-300M aggregate FY2025); ~$150-300M aggregate FY2025 capital return; selected ~25%+ Troendle family + Founder family aggregate ownership; investment-grade pathway pre-credit-rating; FY2026 catalyst: continued capital deployment + selected potential post-deleveraging dividend initiation.
Company Background
Medpace Holdings Inc. (NASDAQ: MEDP) is one of the largest US mid-cap + small-cap biotech-focused Contract Research Organizations (CRO) with FY2025 revenue ~$2.3-2.5B (+8-15% YoY) and adj. EPS ~$13.50-15.00 reflecting continued post-2024 ~$3.0-3.3B aggregate backlog + selected continued post-2024 selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services. The company employs ~6,000+ globally with operations across selected major Cincinnati Ohio + selected various US + Europe + Asia + selected various.
Founded 1992 as Medpace by August Troendle (~33-year heritage; selected pioneer mid-cap biotech-focused CRO commercialization); selected post-1992-2014 selected various private ownership + selected various US + Europe + Asia clinical trial expansion; selected post-2014 $915M aggregate Cinven (UK-based private equity) acquisition; selected post-August 2016 NASDAQ listing IPO via secondary offering ($255M aggregate raised; selected post-Cinven exit through 2021); selected continued post-1992 August Troendle Founder + CEO continuation; selected continued post-2024 selected various ~$3-4B aggregate FY2024-2025 backlog cumulative growth.
Headquartered in Cincinnati Ohio; ~6,000+ employees globally with ~$2.3-2.5B revenue. One primary segment: Clinical Trial Services + Selected Various (~100% revenue ~$2.3-2.5B — selected primary mid-cap biotech + selected various small-cap biotech Phase II + Phase III + selected various therapeutic-focused clinical trial services). End market mix: Mid-cap + small-cap biotech 80%+ revenue ($1.85-2.0B; selected primary mid-cap biotech focus) + Large-cap pharma + selected various 10% ($230-250M) + Government + selected various 5-10% ($120-200M). Therapeutic mix: Oncology ~30%+ revenue + Cardiology + Metabolic ~20% + Neurology + selected various CNS ~15-20% + Antiviral + Infectious Disease ~10% + selected various ~25-30%.
President + CEO August Troendle since 1992 (~33-year tenure as Medpace Founder + CEO); selected ex-various pharmaceutical industry roles + ~40+-year industry career; selected ~25%+ Troendle family + Founder family aggregate ownership; selected continued strategic priorities include mid-cap biotech CRO leadership + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services + selected continued post-2024 selected various biotech funding + selected various clinical trial demand recovery + selected continued post-2024 capital deployment. CFO Kevin Brady (since 2019; ex-various Medpace + selected various roles + ~25-year industry career).
Mid-Cap Biotech CRO Cycle
Medpace mid-cap biotech CRO franchise:
- Aggregate revenue:
$2.3-2.5B FY2025 (+8-15% YoY) - Aggregate backlog:
$3.0-3.3B (+5-10% YoY) - Mid-cap biotech focus: selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership (~80%+ revenue)
- Phase II + Phase III: selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services
- Selected continued post-2024 biotech funding cycle: continued post-2024 selected various biotech funding + selected various clinical trial demand recovery
- Selected continued post-2024 ~$0.50-0.80 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued mid-cap biotech CRO + ~$0.50-0.80 incremental annual EPS contribution.
Therapeutic-Focused Clinical Trial Services
Medpace therapeutic-focused franchise:
- Therapeutic mix: Oncology ~30%+ + Cardiology + Metabolic ~20% + Neurology + CNS ~15-20% + Antiviral + Infectious Disease ~10% + selected various ~25-30%
- US + international clinical trial site network: selected various US + selected various international clinical trial site network
- Selected continued post-2024 selected various therapeutic mix expansion: continued post-2024 selected various
- Selected continued post-2024 ~$0.20-0.30 incremental annual EPS contribution: from continued post-2024 therapeutic mix expansion
FY2026 catalyst: continued therapeutic-focused + ~$0.20-0.30 incremental EPS contribution.
Capital + Cash Position
Medpace capital + cash position framework:
- Cash + investments balance: ~$300-450M aggregate FY2025
- Net debt position: ~$0M aggregate FY2025
- Buybacks: selected modest opportunistic buybacks;
$300-500M aggregate FY2024-2025 buyback program ($150-300M aggregate FY2025) - Aggregate capital return: ~$150-300M FY2025
- Selected ~25%+ Troendle family + Founder family ownership: selected continued post-1992 founding family ownership
FY2026 catalyst: continued capital deployment + selected potential post-deleveraging dividend initiation.
Risks
- Mid-cap biotech CRO cyclical: continued post-2024 mid-cap + small-cap biotech CRO demand cyclical sustainability
- Selected various competitive intensity: IQVIA + ICON + Charles River + selected various US + global CRO competitive
- Selected various biotech funding cycle: continued post-2024 biotech VC funding + selected various biotech IPO cycle
- Selected various clinical trial cancellation: continued post-2024 selected various clinical trial cancellation + selected various
- Selected ~25%+ Troendle family + Founder family ownership: selected continued ~25%+ Troendle family + Founder family aggregate ownership concentration governance
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | $2.3-2.5B | $2.11B | $1.89B | $1.46B | $2.5-2.75B |
| Adj. EBITDA | $470-540M | $440M | $390M | $290M | $530-610M |
| Adj. EPS (USD) | $13.50-15.00 | $11.93 | $9.61 | $6.85 | $14.50-16.50 |
| Adj. EBITDA margin | 21-22% | 21% | 21% | 20% | 21-22% |
| Backlog | $3.0-3.3B | $2.95B | $2.85B | $2.5B | $3.2-3.5B |
| Capital + cash | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Cash + investments | $300-450M | $390M | $350-500M |
| Net debt | $0M | $0M | $0M |
| Buybacks | $150-300M | $250M | $200-400M |
| Total return | $150-300M | $250M | $200-400M |
Market Evaluation
Medpace Holdings trades at selected ~22-26x FY2026 P/E premium vs IQVIA (~14-17x) + ICON (~16-19x) + Charles River (~14-17x) + selected various US + global CRO peers reflecting selected continued ~$3.0-3.3B aggregate backlog + selected continued post-2024 selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership + selected ~25%+ Troendle family + Founder family aggregate ownership + selected continued post-2024 ~$300-450M aggregate cash + investments balance. Selected re-rating catalysts include: (1) continued mid-cap biotech CRO cycle + ~+8-15% YoY revenue growth; (2) selected continued post-2024 therapeutic-focused clinical trial services; (3) selected continued post-2024 biotech funding + clinical trial demand recovery; (4) ~$150-400M aggregate annual buybacks + selected pathway to dividend initiation; (5) selected continued ~25%+ Troendle family + Founder family aggregate ownership.
Mid-Cap Biotech + Therapeutic Focus Strategic Differentiation Deep Dive
Medpace Holdings mid-cap biotech-focused CRO franchise + selected continued post-2024 therapeutic-focused (oncology + cardiology + neurology + selected various) clinical trial services + selected ~25%+ Troendle family + Founder family aggregate ownership represent selected primary strategic differentiation thesis vs traditional US + global CRO peers (IQVIA + ICON + Charles River + selected various). Selected $2.3-2.5B aggregate revenue FY2025 (+8-15% YoY) + selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership (~80%+ revenue mix) + selected continued post-2024 $3.0-3.3B aggregate backlog (+5-10% YoY) + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services + selected various biotech funding + selected various clinical trial demand recovery + selected continued post-2024 ~$0.50-0.80 incremental annual EPS contribution supports selected primary mid-cap biotech CRO cycle thesis. Selected continued post-2024 selected primary therapeutic-focused (oncology ~30%+ + cardiology + metabolic ~20% + neurology + CNS ~15-20% + antiviral + infectious disease ~10% + selected various ~25-30%) clinical trial service capability + selected various US + selected various international clinical trial site network + selected various ~$0.20-0.30 incremental annual EPS contribution from selected various therapeutic mix expansion supports selected continued post-2024 Therapeutic-focused clinical trial services franchise. Selected post-1992 August Troendle Founder + CEO appointment (~33-year tenure as Medpace Founder + CEO + ~40+-year industry career) + selected ~25%+ Troendle family + Founder family aggregate ownership + selected post-2014 $915M aggregate Cinven (UK-based private equity) acquisition + selected post-August 2016 NASDAQ listing IPO via secondary offering ($255M aggregate raised) + selected post-2024 ~$300-450M aggregate cash + investments balance + selected ~$0M aggregate net debt position + selected ~$300-500M aggregate FY2024-2025 buyback program supports selected continued post-2024 capital flexibility. FY2026 catalyst: continued mid-cap biotech CRO + therapeutic-focused + ~$0.50-0.80 incremental annual EPS contribution.
FY2026 thesis: Mid-cap biotech CRO cycle + Therapeutic-focused clinical trial services + selected continued post-2024 selected various biotech funding + clinical trial demand recovery + ~$300-500M aggregate cash + investments balance + ~$0M aggregate net debt + ~$150-400M aggregate annual buybacks + selected continued ~25%+ Troendle family + Founder family aggregate ownership + selected potential post-2024 dividend initiation.
